The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•25 March 2026•

1 min read

Seaport Therapeutics Validates Glyph Platform in Science Translational Medicine Study

Key Facts

1Seaport Therapeutics, founded by PureTech, announced the publication of research in Science Translational Medicine regarding SPT-300.

2SPT-300 is the first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans.

3The Glyph platform uses technology to enable oral absorption via the lymphatic system to bypass first-pass metabolism.

Seaport Therapeutics, a biotech firm founded by PureTech Health, has announced the publication of peer-reviewed research in the prestigious journal Science Translational Medicine regarding its SPT-300 candidate. The study identifies SPT-300 as the first triglyceride-mimetic prodrug to successfully achieve therapeutically relevant drug levels in human subjects. Utilizing the proprietary Glyph platform, the technology enables oral absorption through the lymphatic system, effectively bypassing first-pass metabolism in the liver. This publication serves as a critical scientific validation for the drug delivery platform, which aims to enhance the bioavailability of neuropsychiatric treatments. The successful demonstration of the Glyph platform's capabilities is expected to provide a positive catalyst for the valuation of its parent company, PureTech Health. This milestone underscores the significant potential for developing more effective oral therapies within the global biotechnology sector.

Create Free Account